0001213900-22-041618.txt : 20220726 0001213900-22-041618.hdr.sgml : 20220726 20220726133239 ACCESSION NUMBER: 0001213900-22-041618 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220725 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220726 DATE AS OF CHANGE: 20220726 FILER: COMPANY DATA: COMPANY CONFORMED NAME: InMed Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001728328 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39685 FILM NUMBER: 221106112 BUSINESS ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 BUSINESS PHONE: (604) 669-7207 MAIL ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 8-K 1 ea163353-8k_inmedpharma.htm CURRENT REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 25, 2022

INMED PHARMACEUTICALS INC.

(Exact Name of Company as Specified in Charter)

British Columbia		001-39685		98-1428279
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

InMed Pharmaceuticals Inc.

Suite 310 - 815 W. Hastings Street,

Vancouver, B.C.

Canada

V6C 1B4

(Address of Principal Executive Offices)

(Zip Code)

Company’s telephone number, including area code: (604) 669-7207

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares, no par value		INM		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On July 25, 2022, the Company provided an update on its Phase 2 clinical trial using investigational drug INM-755 cannabinol (“CBN”) cream for the treatment of patients with epidermolysis bullosa (“EB”).

The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

The following exhibits shall be deemed to be furnished, and not filed:

Exhibit No.		Description

99.1		News release, dated July 25, 2022
104		Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	INMED PHARMACEUTICALS INC.

Date: July 26, 2022	By:	/s/ Eric A Adams
		Eric A Adam
		President & CEO

2

EX-99.1 2 ea163353ex99-1_inmedpharma.htm NEWS RELEASE, DATED JULY 25, 2022

Exhibit 99.1

cid:95921F3E-280E-4CB5-B907-9322A561875D@vc.shawcable.net

NASDAQ: INM

Suite 310-815 W. Hastings St.

Vancouver, BC, Canada V6C 1B4

Tel: +1.604.669.7207

Email: info@inmedpharma.com

www.inmedpharma.com

InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa

●

Phase 2 clinical trial recently expanded to include adolescents following independent review of early safety data

●

First adolescent patient with EB enrolled into clinical trial and completed treatment

●

International patent granted for the use of cannabinol for the treatment of epidermolysis bullosa

Vancouver, BC – July 25, 2022 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today provided an update on its Phase 2 clinical trial using investigational drug INM-755 cannabinol (“CBN”) cream for the treatment of patients with epidermolysis bullosa (“EB”).

Adolescent patients now eligible to participate in clinical trial

Based on the safety data of the first five adult patients who completed the Phase 2 study, an independent Data Monitoring Committee (“DMC”) agreed it is safe to allow the enrollment of adolescent patients with EB, defined as persons aged twelve to seventeen, into InMed’s Phase 2 clinical trial evaluating INM-755 CBN cream for the treatment of EB. The first adult patient was enrolled in December 2021 and, to date, nine patients have been enrolled in the study. The inclusion of adolescents will have a positive impact in the enrollment rate for the remainder of the clinical trial.

First adolescent patient enrolled into clinical trial

With the DMC approval to enroll adolescent patients into InMed’s INM-755 Phase 2 clinical trial, the first adolescent patient with EB has been enrolled into the clinical trial and has completed treatment at the clinical site in Greece.

Patent granted in Japan

InMed has recently been granted a patent for the use of CBN in the treatment of EB in Japan. This patent allows for the use of topically administered CBN in patients with epidermolysis bullosa simplex (EBS). The Company’s overall patent strategy is to continue to prosecute patent applications in other jurisdictions including Europe and the United States.

Eight clinical trial sites fully activated

InMed’s Phase 2 clinical trial now has eight clinical trial sites fully activated to screen and enroll patients. Two more sites are expected to be fully activated soon. The clinical trial is taking place in seven countries including Austria, Germany, Greece, France, Italy, Israel and Spain. The planned clinical site in Serbia will not be participating in the study due to staffing capacity issues related to the ongoing impact of the COVID-19 virus.

“We are pleased that the initial safety data from InMed’s Phase 2 EB clinical trial has allowed the inclusion of adolescent patients,” stated Alexandra Mancini, Senior Vice President of Clinical and Regulatory Affairs at InMed. “With the inclusion of adolescents and increased number of patients available for screening, the target remains to complete enrollment of 20 patients in 2022.”

The Phase 2 study, 755-201-EB, is designed to enroll up to 20 patients. All four subtypes of inherited EB, being EB Simplex, Dystrophic EB, Junctional EB, and Kindler Syndrome, are eligible for this study. InMed will evaluate the safety of INM-755 (cannabinol) cream and its preliminary efficacy in treating symptoms and healing wounds over a 28-day period. The study uses a within-patient, double-blind design whereby matched index areas will be randomized to INM-755 (cannabinol) cream or vehicle cream as a control. To learn more about this EB study, view the detailed study description on the National Institutes of Health (NIH) clinicaltrials.gov website.

Learn more about InMed’s INM-755 EB study: https://www.inmedpharma.com/pharmaceutical/inm-755-for-epidermolysis-bullosa/

What is epidermolysis bullosa?

Epidermolysis bullosa, or EB, is a group of rare genetic skin diseases characterized by fragile skin that can lead to extensive blistering and wounding. It affects skin and mucous membranes, particularly of the gastrointestinal tract, genitourinary and respiratory systems. It is a debilitating disease affecting a small number of people, thus earning it an orphan-disease status. The disease has no definitive cure and all currently approved treatments are directed towards symptom relief. Learn more: https://www.inmedpharma.com/learn/what-is-epidermolysis-bullosa/.

About InMed: InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary BayMedica LLC, the Company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is also a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com and www.baymedica.com.

Investor Contact:

Colin Clancy

Vice President, Investor Relations & Corporate Communications

T: +1.604.416.0999

E: cclancy@inmedpharma.com

2

Cautionary Note Regarding Forward-Looking Information:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: an update on Phase 2 clinical trial investigating INM-755 cannabinol cream for EB; the Phase 2 clinical trial recently being expanded to include adolescents following independent review of early safety data; the inclusion of adolescents having a positive impact in the enrollment rate for the remainder of the clinical trial and the target remains to complete enrollment of 20 patients in 2022; being granted a patent for the use of CBN in the treatment of EB in Japan; continuing to prosecute patents in other jurisdictions; having eight clinical trial sites fully activated to screen and enroll patients with two more sites expected to be fully activated soon; being able to demonstrate that cannabinol cream is a safe and effective treatment for epidermolysis bullosa; continuing to prosecute patents in other jurisdictions, including being a global leader in the research, development, manufacturing and commercialization of rare cannabinoids; and delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs.

With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: the ability to obtain all necessary regulatory approvals on a timely basis, or at all; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed’s stand-alone business is disclosed in InMed’s Annual Report on Form 10-K and other filings with the Security and Exchange Commission on www.sec.gov.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

3

EX-101.SCH 3 inm-20220725.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 inm-20220725_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 inm-20220725_pre.xml XBRL PRESENTATION FILE GRAPHIC 6 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# H'!PD'!@H)" D+"PH,#QD0#PX. M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_ MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T] M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P 1" !R -8# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#V:D) !)( M'-16#*&4@@]"* MC>XAB;;)-&K>C, :Y/4Y9/!]PL5ADVVHGR8(F;(AF/0C/\/^%:MIX3TV.$?: MX%N[EN9)ILL6;O3<4E=L2DWH:OVRV_Y^(?\ OL4^.>*4D1RHY'7:P-9W_",: M-_T#;?\ [YJIJ'ABWAA-SHT0M;Z'YHS&1T%%4M)U&/5-. MBNHQM+##IW1AU!^AJ[4M6*3N%%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 9NN:BVG6'[@;KJ=A%;IZN>GY=:DTC3ETK3H[=3NN:$K[C;L<'X]\:(NL MP *)8MV N,E8O2?"VL#5])0LX>:(!78?Q@C*M^(Y_.N!ELY- M.V6?D[Y86\AM[MG=V/7H1R/QK>\.^&EO5NK];FZM_-(2%XI2 =O!;'IGI6\X MKEW,(2?-L=U161H5_/.L]E?D?;K1MDAZ;U_A(3_:%Y8Z3#S(TJW$C#_EFBGK^)XK?IRV3%'=A111 M4E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 -=%DC9'4,K @@]Q M6'H;MIE[-HD[$B,>;:L?XHCV^JGBMZL_5=(BU18F,DD,\)W131G#(?\ "JB^ MC):ZHI:]*]_<0Z+;L0UQ\]PP_@B'7\3TK:BB2&)(HU"H@"JHZ "N.M]-U&U\ M574,NLRK)=1*\4IA4^8%X*^Q%;/]D:K_ -!Z;_OPE5)*R5R4WJ[&)XW CU&U M:VSYLBXO-@R5@SR_U&3@^YKL+6.&*TB2V"B%4 3;TVXXJCIVA0V0G>:22[GN M1MFEFY+#TQV'M56+P[=6:F*PUBX@MQ]R)D5]GL">U#::2OL"33O8->B>PN8= M;MU):W^2X5?XXCU_$=:U+C4+>WTY[YY!]G6/S-P[CM6)JMG?6.F7$]SKLIB5 M#E?LZ?-G@#\:@T/PM.=+L$U>]FG2)0XM2 J ]0#CKBG96NV%W?1&EX>M)3'+ MJ=XN+N].\@_\LT_A7\JVJ2EK-N[N6E9!1112&%%%)0 M%%% !1110 4444 % M%%% !1110 45#=W M+.:X92PBC9R!WP,UP_@SXFGQAX@:PCTW[+"L#2[VEW, M<$#&,8[T["N=]1112&%%%% &7KVGR7MDLEK\MY;-YL#?[0[?0CBK&E:A'JFG M1748QO&&4]58=0?H:N5ARZ/?6E]-NMTK38M*L5MXBSG)9W;J['J37' M_$/_ )"%G_UR;^=:TFG-(SJ*T&:?@&1Y-*N3([.1/U9B?X1755Q/A*\:P\*Z ME=*H=H7+A2>#A169/XZU:0DQF"$>BIG^=$J4IS=@C448JYZ317EX\9:R"#]K M4^QC7_"NA\/^-3>W*6FHHB22'"2IP"?0CM2E0DE<<:T6['6NXC1G;HHR:^8M M.\4ZEI>OQZI%=3NT^*F'6Y4CZ3TS48-6TVWOK1]\%Q&)$/ ML?ZU:KR7X)^)-\5QH%P_*9N+;/\ =/WU_ X/XFO6JAJS*3NC+\2:Y#X0>8VT[G&1C.,<]*ZOXR> M(7U'6K;0+,ETMB&E5?XYF^ZOX _^/5R7B#1&\(^)K.T=BTL26\\A[;S@MCV! M%:16A,GJ?3%%137$5O;O<32*D,:EV=C@*H&237D.O_&2^N[XVGA:T&PMM2:2 M,O)*?]E.P^N:S2;*;L>QT5X5-X^\?Z)LGU."186/_+S9[5/MD8Q^=>D>!?'E MKXRMI$,?V:_@ ,L&<@C^\I[C^5-Q:!.YUM%8_B;Q-8^%=)>^U!CC.V.)?O2M MV4?X]J\CN?BQXKUF]9-&MDA7^&*& S.![D_X"A1;!NQ[/K'_ "!;[_KWD_\ M037B?P3_ .1S?_KQ?_T):D;XG>*].BEMM>LA)%/&T?[ZW,+ED__H2U5K)DWNT>\4445F6%%%% !1110 4444 %<%\0_P#D(6?_ %R; M^==[7!?$/_D(6?\ UR;^=:T/C1G5^ 30?^1'UCZM_P"@BLGPI&DOB2T21%=2 M6RK#(^Z:UM!_Y$?6/JW_ *"*R_"/_(SV?U;_ -!-='29AUB>DS:=:7$)BFMH M6C88(*"O)]3M?[.U2YMT)_^!R*]@KRCQ-_R,>H?]=/Z"L\.W=HTKI63 M.R\67A;X;:CN ^!4>=1UB3^[#$OYEO\*Z[QI)Y7PANC_> MLXE_,J*YSX$Q_N=;D_VXE_1C66R9IU1S7BNSF^'OQ)CO[)2MNTGVJ%1P"A/S MI_,?0BO:=1\16=AX7EUS>'MEM_.0_P!_(^4?B2!7.?%GP[_;7A)[J%-UUIQ, MZX')3^,?ES^%>/W/BVZN? ]IX=;<8K>3JJ_@23^5%N9(+V.C^%VCS> M*/&L^MZ@/,2U7XRAD'\=DI_)F%>H_#WPZ/#?A& MUMY$VW,P\^X]=[=OP&!^%><_'./'B'37_O6C+^3G_&A.\@:M$W/BQKTD/@C2 M[.%RIU(*TA'=%4$C\25IOPBL=(TO0SJMYTGWV)_A3?"GPH@\4^'K?5%U/:;PV0\;$ MJ.>_8_A76?\ "AX_^@V?_ 8?_%5;TKX+KIFK6=Z-:9_LTR2[/LX&[:3_T$UXG\$_^1S?_ *\7_P#0EHCLP>Z/>:***@H**** "BBB@ HHHH *X+XA M_P#(0LO^N3?SKO:RM8T[2+MHY=6\D%051I)=G]15TY*,KLB<7*-DS^K?^@FNZ6TT;3M/%LOEI:W\@B4!BPD=AP ?H/TI]IX: MTNQNDN+:U"2IG:VXG';UK7VJM+S,_9O3R-2O*/$W_(QZA_UT_H*]8K)NO#&D MWES)/<6@>60Y9MS#)_.HI34'=EU(.:LCD_B')Y?PC _OI;K_ ./+6?\ M,: M/JS^MR@_)/\ Z]>@:EX?T[5])73;ZW$MFNW$>XC[O3D'-)H?AS3/#=O)!I-L M+>*5][J&)R<8SR?:IHT5*;0VKA7C?QUC_ .)CH\GK%*OZK7LE8^N^%M'\2M#_ M &M:+<-!GR\NPVYQGH1Z"B+L[@U='%OX;?Q?\&M)AM\&\MX%EM\G[S+D%<^X MR/RKB_ OCVX\#W%QIVHVLSV;29DAQB2!^A(!]<$)+^6U5 MKQIX55Y(OM!^56SM/3OM/?M74Z#X1T7PT6;2;%(9'7:\A)9V'7!)I/EZ#5SA M?C#X-GU!8]>T^$RR0Q^7=1H,DH.0X'?&3GV^E9O@CXN1:9ID6G:_'-)' H2* MYB&X[1T##V]17LU&9=,N889;J226)D4+ 1R01WQ7$_!08\:2 ]19/_P"A+7>Q_!OPNC9:.\D' MHUP6PA\9Z0^J6_GP?8[C"_9S-\VZ/G: ??FNQK.FTKSO$%IJ M?G$&W@DA\O;][>5.<^VW]:: X.XM)?[22?1[>33-/N-2M1;+/"54RA9-\BQ' M! (*CMDC-=(-6O\ 3KC4M/U;4;1#!;),'G-;.JZ7_: M;6)\TQ_9+I+G[N=VT$8]NM9VM^%O[7OWO$O#!,(X1%^[#!'BD,BL03\PYP1^ MM.XC"_X3&^BMM3@@O;:^E@%NT-T;=H\"67RR&3/)'48ZYK4NIM=@UBPTA=5@ M+W,H7&,\XQ6=/X1OUM]0L['5(8K/40?/66VWNK% C%6 M##J .#G%&@:D\-[J^O7UY_9MW!8VEG*(07@\UY9-JLV>1A1N XYX-85QXZN6 MBN]0M[^S1+>5UCTYH&:2=$8J.ZVM-% M/;^8-X4+O7##!(49'(XHM=!U/2Y7BTO5(8["24R^3-;;VC+-N<(P8<$DD @X MS1H ^QUJXNK#6YV" V<\B0_+CY5C5AGWR:QO#\FI:IK]S>0WD5N9;*QEG0P; MPY9&)Q\PV]_6M.[\.:@MQJ)TO4HH+;427FBFM_,V.5"ED(8=0!P<\T6_AF]T MRZBETK4HXE-M#;3K-;[]XB! 9<,,$@D=Q2 S],U>_P!0:WTO2Q:6,C_:9YI5 M@RJ(L[(H5,@%F/))]#ZU/KFJW>DQQPOXBLX[V.$N8VLBWFG)P6 8E%Z#\_I4 MZ>$Y[+[/<:;J AO8#,-\D.Y)8Y)#(49<@\$C!!_G2#P[K$-W83P.3C).! MUQ70^&KU[ZUDF.L6^IH2 &B@\HQGN&&21]#@BJMGX8N]*V-INI(CBPBM&,MO MO!:/.U\;ACAF!'T]*M:1HEQ9ZK=ZG?7,,UU=1I$1!#Y2!5)()&22WS'DGI@4 M.P&U1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% <% !1110 4444 %%%% !1110 4444 %%%% '_V0$! end XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	Jul. 25, 2022
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jul. 25, 2022
Entity File Number	001-39685
Entity Registrant Name	INMED PHARMACEUTICALS INC.
Entity Central Index Key	0001728328
Entity Tax Identification Number	98-1428279
Entity Incorporation, State or Country Code	A1
Entity Address, Address Line One	Suite 310 - 815 W. Hastings Street
Entity Address, City or Town	Vancouver, B.C.
Entity Address, Country	CA
Entity Address, Postal Zip Code	V6C 1B4
City Area Code	604
Local Phone Number	669-7207
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Shares, no par value
Trading Symbol	INM
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false

XML 8 ea163353-8k_inmedpharma_htm.xml IDEA: XBRL DOCUMENT 0001728328 2022-07-25 2022-07-25 iso4217:USD shares iso4217:USD shares 0001728328 false A1 8-K 2022-07-25 INMED PHARMACEUTICALS INC. 001-39685 98-1428279 Suite 310 - 815 W. Hastings Street Vancouver, B.C. CA V6C 1B4 604 669-7207 false false false false Common Shares, no par value INM NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://inmedpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea163353-8k_inmedpharma.htm ea163353ex99-1_inmedpharma.htm inm-20220725.xsd inm-20220725_lab.xml inm-20220725_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea163353-8k_inmedpharma.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "ea163353-8k_inmedpharma.htm" ] }, "labelLink": { "local": [ "inm-20220725_lab.xml" ] }, "presentationLink": { "local": [ "inm-20220725_pre.xml" ] }, "schema": { "local": [ "inm-20220725.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "INM", "nsuri": "http://inmedpharma.com/20220725", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea163353-8k_inmedpharma.htm", "contextRef": "From2022-07-25to2022-07-25", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://inmedpharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea163353-8k_inmedpharma.htm", "contextRef": "From2022-07-25to2022-07-25", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 16 0001213900-22-041618-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-22-041618-xbrl.zip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